Wayland Group Corp Aktie Canadian Securities Exchange
Aktien
CA5667241007
Pharmazeutika
Umsatz 2016 | 4.06 5.55 3.71 | Umsatz 2017 | 3.22 4.41 2.94 | Marktwert | 203 Mio. 278 Mio. 186 Mio. |
---|---|---|---|---|---|
Nettoergebnis 2016 | -8 Mio. -10.94 Mio. -7.31 Mio. | Nettoergebnis 2017 | -67 Mio. -91.58 Mio. -61.19 Mio. | EV / Sales 2016 * | - |
Nettoschuld 2016 | 9.13 12.48 8.34 | Nettoliquidität 2017 | 0.42 0.57 0.38 | EV / Sales 2017 | 63’046’727 x |
KGV 2016 * |
-
| KGV 2017 |
-2.13
x | Beschäftigte | - |
Rendite 2016 * |
-
| Rendite 2017 |
-
| Streubesitz | 100% |
Manager | Titel | Alter | Seit |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
% 1. Jan. | Kap. | |
---|---|---|
+35.04% | 5.92 Mrd. | |
-15.13% | 4.51 Mrd. | |
-9.75% | 3.15 Mrd. | |
+2.14% | 3.1 Mrd. | |
-6.82% | 2.42 Mrd. | |
+47.87% | 1.97 Mrd. | |
-7.89% | 1.68 Mrd. | |
+0.09% | 1.65 Mrd. | |
-12.97% | 1.53 Mrd. |